All In Biotech

Drug Trial Radar · NCT04341428

Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis

A Multi-center, Double-Blind, Randomized, Active-controlled, Parallel-group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 as Maintenance Therapy in Patients With Healed Erosive Esophagitis

Last checked: Nov 19, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 406 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

406

Planned (sponsor's estimate)

Start

Jul 2, 2020

Primary completion

Aug 30, 2021

Study completion Dec 30, 2021

Sponsor

Sponsor type
Industry
First posted
Apr 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to demonstrate the noninferiority of DWP14012 to Lansoprazole 15 mg in the maintenance effect of treatment and confirm the safety of DWP14012 in patients with healed erosive esophagitis confirmed on EGD after medication treatment.

Conditions

  • Healed Erosive Esophagitis

Interventions

  • DWP14012 20 mgDrug

    DWP14012 20 mg, tablet, orally, once daily for up to 24 weeks

  • DWP14012 20 mg placeboDrug

    DWP14012 20 mg placebo-matching tablet, orally, once daily for up to 24 weeks

  • Lansoprazole 15 mgDrug

    Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks

  • Lansoprazole 15 mg PlaceboDrug

    Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion (%) of subjects with remission maintained on esophagogastroduodenoscopy by Week 24Time frame: at 24 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea, Yeouido ST. Mary's Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.